Immune checkpoint inhibitor-associated diabetes mellitus: the case series report.

This report aims to better define the rare adverse event of immune checkpoint inhibitor-associated diabetes mellitus(ICI-DM). We present 10 cases of patients including six of the patients had no prior history of diabetes, while four had varying degrees of pre-existing diabetes. Eight who received anti-PD-1 combination therapy, one who received anti-PD-1 monotherapy, and one who received dual anti-PD-1/CTLA-4 therapy. The mean time from initiation of immunotherapy to the onset of ICI-DM was 245.4 days (median, 149 days; range, 11 to 787 days). Diabetic ketoacidosis (DKA) occurred in 60% (6/10) of the patients, with a median fasting blood glucose level of 25.85 mmol/L (range, 14.76 to 38.23 mmol/L), and all had C-peptide levels below the normal range. Through a retrospective analysis of the clinical data of these 10 patients, we found that monitoring fasting blood glucose and HbA1c is crucial for patients undergoing or having undergone immunotherapy, as rapid pancreatic β-cell destruction can be observed in those who develop ICI-DM, potentially due to disruption of the PD-1/PD-L1 pathway.